Feb 26, 2020 - REGENXBIO, Inc. (NASDAQ:RGNX) Q4 2019 Earnings Conference Call February 26, 2020 4:30 PM ET Company Participants Patrick Christmas - Senior Vice President and General Counsel Kenneth Mills - President
Feb 26, 2020 - RGNX earnings call for the period ending December 31, 2019.
Jan 10, 2020 - Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.
Dec 13, 2019 - Gainers: GVA +4.8%. CYTK +3.3%. TEN +3.1%. BRFS +2.1%. SWN +2%.Losers: AUDC -3.8%. CX -2.6%. NK -1.4%. RGNX -1%.
Nov 05, 2019 - REGENXBIO, Inc. (NASDAQ:RGNX) Q3 2019 Earnings Conference Call November 5, 2019 04:30 PM ET Company Participants Patrick Christmas - Senior Vice President and General Counsel Kenneth Mills - President
Nov 05, 2019 - RGNX earnings call for the period ending September 30, 2019.
Nov 05, 2019 - Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Oct 15, 2019 - Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
Oct 11, 2019 - These companies' collaborations with bigger businesses validates their science -- and paves the way for future revenues and profits.
Oct 10, 2019 - The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.